Friess Associates’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Friess Associates’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-378,734	Closed	-$6.29M	–	153
2019 Q4	$6.29M	Buy	378,734 +227,913	+151%	+$3.7M	0.44%	70
2019 Q3	$2.51M	Buy	+150,821	New	+$2.09M	0.19%	84
2015 Q4	–	Sell	-48,200	Closed	-$651K	–	189
2015 Q3	$651K	Hold	48,200	–	–	0.06%	97
2015 Q2	$668K	Sell	48,200 -1,185	-2%	-$16K	0.06%	98
2015 Q1	$695K	Buy	+49,385	New	+$672K	0.06%	95
2014 Q3	–	Sell	-24,000	Closed	-$404K	–	176
2014 Q2	$404K	Buy	24,000 +1,600	+7%	+$28.8K	0.03%	99
2014 Q1	$450K	Buy	+22,400	New	+$485K	0.04%	98

Other funds holding OXFD

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Grandeur Peak Global Advisors Salt Lake City, Utah $432M AUM 42.58% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Friess Associates's OXFD Position: Q1 2020 in Review

Friess Associates sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2020, closing a stake of 378,734 shares — an estimated $6.29M sold.

Friess Associates first reported a position in OXFD in Q1 2014 and held it in 7 quarters. The position peaked at $6.29M in Q4 2019. 65 funds tracked by Wall St. Rank hold OXFD as of Q1 2020.

Friess Associates reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2020 after selling out during the quarter.
Friess Associates sold 378,734 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2020, an estimated $6.29M.
Friess Associates first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q1 2014 and held it in 7 quarters.
Friess Associates's Oxford Immunotec Global PLC Ordinary Shares position peaked at $6.29M in Q4 2019.
65 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2020.

Based on Friess Associates's 13F filing for Q1 2020, filed 15 May 2020.